np-g2-044
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2017 (NCT03199586)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- FascinINHIBITOR
FSCN1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1occc1C(=O)Nc1nn(Cc2ccc(C(F)(F)F)cc2)c2ccccc12- Mol. weight
- 399.37 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297473 ↗
Also known as
- np-g2-044
- np-g2-044
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05023486 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Novita Pharmaceuticals |
| NCT03199586 | Phase 1 | Sep 1, 2017 | Novita Pharmaceuticals, Translational Drug Development |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novita Pharmaceuticals | For profit | 2 | 2 | 2 | 2017 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1